Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Centre René Gauducheau.
Recruitment status was  Recruiting
Information provided by:
Centre René Gauducheau Identifier:
First received: March 28, 2011
Last updated: March 29, 2011
Last verified: January 2011
The aim of the study is a medico-economic evaluation to estimate a cost differential between three modalities of Intensity-Modulated Radiation Therapy for cancers of the prostate, cervix and anal canal with pelvic lymph node irradiation : treatment with helical Tomotherapy and dynamic arc therapy using two different technologies: RapidArc or VMAT.

Condition Intervention
Prostate Cancer
Cervical Cancer
Anal Canal Cancers
Radiation: Intensity-Modulated Radiation Therapy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Medico-economic Evaluation Comparing Conformal Radiotherapy With Intensity Modulation (IMRT) Performed by, Helical Tomotherapy (Hi Art) and Dynamic Arc Therapy (RapidArc, VMAT) in Cancers With Pelvic Lymph Node Irradiation (Prostate, Cervix, Anal Canal)

Resource links provided by NLM:

Further study details as provided by Centre René Gauducheau:

Primary Outcome Measures:
  • Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT). [ Time Frame: 2 months ] [ Designated as safety issue: No ]
    Costs of the devices, maintenance costs ; personnel costs directly related to the medical therapeutic procedure (physicians, medical physicists, dosimetry, technicians).

Secondary Outcome Measures:
  • Others economic criteria [ Time Frame: 2 months ] [ Designated as safety issue: No ]
    • the estimation of the cost differential by individualizing the preparation phase and phase radiation
    • the analysis of the possible impact of learning in helical tomotherapy and dynamic arc therapy with VMAT and RapidArc measured on direct costs (depending on the age of implantation and equipment)

  • clinical response and safety of the treatment by radiotherapy [ Time Frame: 18 Months (cervix and canal anal) or 36 months (prostate) ] [ Designated as safety issue: Yes ]
    • Assess the skin and mucosal toxicity (acute, delayed) : CTCAEv3
    • Assess the prognostic factors of onset of toxicity
    • Assess oncological results

Estimated Enrollment: 120
Study Start Date: March 2011
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • WHO performance index ≤ 2
  • Age > 18 years
  • histologically proven carcinoma: Anal canal cancer locally advanced (> 4 cm and / or N1 to N3) under irradiation on pelvic and inguinal lymph nodes with concurrent chemotherapy. The boost with brachytherapy are accepted Prostate cancer with pelvic lymph nodes and radiation or hormone therapy Cervical Cancer under a purely medical treatment involving irradiation on pelvic lymph nodes and primary tumor with concurrent chemotherapy without surgery. The Boost by external radiotherapy or brachytherapy are accepted.
  • The investigator must ensure that the patient has not expressed its opposition to participate in this study. The signing of a consent form is optional;

Exclusion Criteria:

  • History of invasive cancer other than basal cell carcinomas.
  • Indication of re-irradiation
  • para-aortic radiotherapy associated with pelvic irradiation.
  • post-operative radiotherapy.
  • geographical distance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01325961

Institut Sainte Catherine Not yet recruiting
Avignon, France, 84000
Contact: Nicolas Pourel, MD         
Principal Investigator: Nicolas Pourel, MD         
Sub-Investigator: Bruno Chauvet, MD         
Sub-Investigator: Mineur Laurent, MD         
Sub-Investigator: Gaëtan de RAuglaudre, MD         
Institut Bergonié Not yet recruiting
Bordeaux, France, 33000
Contact: Guy Kantor, MD         
Principal Investigator: Guy Kantor, MD         
Centre Léon Bérard Not yet recruiting
Lyon, France, 69373
Contact: Pascal Pommier, MD         
Principal Investigator: Pascal Pommier, MD         
Institut Paoli Calmette Not yet recruiting
Marseille, France, 13273
Contact: Michel Resbeut, MD         
Principal Investigator: Michel Resbeut, MD         
Sub-Investigator: Mathieu Minsat, MD         
Sub-Investigator: Laurence Moureau- Zabotto, MD         
Sub-Investigator: Agnes Richard- Tallet, MD         
Sub-Investigator: Naji Salem, MD         
Sub-Investigator: Gonzague Casabianca, MD         
Assistance publique des Hôpitaux de Marseille Not yet recruiting
Marseille, France, 13385
Contact: Didier Cowen, MD         
Principal Investigator: Didier Cowen, MD         
Hôpital Clinique Claude Bernard Not yet recruiting
Metz, France, 57 070
Contact: Guillaume Faure, MD         
Principal Investigator: Guillaume Faure, MD         
Groupe Oncorad Not yet recruiting
Montauban, France, 82000
Contact: Philippe Dudouet, MD         
Principal Investigator: dudouet Dudouet, MD         
Sub-Investigator: Igor Latorzeff, MD         
Centre Val d'Aurelle Not yet recruiting
Montpellier, France, 34298
Contact: David Azria, MD         
Principal Investigator: David Azria, MD         
Sub-Investigator: Christine Kerr, MD         
Centre Alexis Vautrin Not yet recruiting
Nancy, France, 54500
Contact: Didier Peiffert, MD         
Principal Investigator: Didier Peiffert, MD         
Sub-Investigator: Véronique Beckendorf, MD         
Sub-Investigator: Claire Brunaud, MD         
Institut Curie Not yet recruiting
Paris, France, 75013
Contact: Campitelli, MD         
Principal Investigator: Campitelli, MD         
Sub-Investigator: De LA ROCHEFORDIERE., MD         
Hôpital Européen Georges Pompidou Not yet recruiting
Paris, France, 75015
Contact: Philippe Giraud, MD         
Principal Investigator: Philippe Giraud, MD         
Sub-Investigator: Martin Housset, MD         
Sub-Investigator: Catherine Durdux, MD         
Centre René Gauducheau Recruiting
Saint Herblain, France
Contact: Marc-André Mahé   
Centre Paul Strauss Not yet recruiting
Strasbourg, France, 67065
Contact: Georges Noel, MD         
Sub-Investigator: Christian Borel, MD         
Sub-Investigator: Marius Pop, MD         
Institut Claudius Regaud Not yet recruiting
Toulouse, France, 31000
Contact: Jean-Marc Bachaud, MD         
Principal Investigator: Jean-Marc Bachaud, MD         
Sub-Investigator: Martine Delannes, MD         
Groupe Oncorad Not yet recruiting
Toulouse, France, 31300
Contact: Denis Franck, MD         
Principal Investigator: Denis Franck, MD         
Sub-Investigator: Igor Latorzeff, MD         
Sub-Investigator: Philippe Dudouet, MD         
Sponsors and Collaborators
Centre René Gauducheau
  More Information

Responsible Party: Mme Scotet-Cérato,, Centre René Gauducheau Identifier: NCT01325961     History of Changes
Other Study ID Numbers: BRD 10/12-O 
Study First Received: March 28, 2011
Last Updated: March 29, 2011
Health Authority: France : French Health Products Safety Agency (AFSSAPS)

Keywords provided by Centre René Gauducheau:
prostate, cervical and anal canal cancers with pelvic lymph node irradiation

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Anus Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases processed this record on August 24, 2016